Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

President Donald Trump said his administration is prepared to increase the tariffs it plans to impose on pharmaceuticals up ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

The sell-off of this pharmaceutical giant might be overdone. Once a market darling during the early pandemic years, Pfizer ( ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

(Reuters) -U.S. drugmaker Pfizer raised its full-year profit forecast on Tuesday after reporting better-than-expected results ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.